Low Rates of Antifungal Therapeutic Drug Monitoring Among Inpatients Who Received Itraconazole, Posaconazole, or Voriconazole, United States, 2019-2021.

Kaitlin BenedictJeremy A W GoldMitsuru TodaGeorge R ThompsonNathan P WiederholdDallas J Smith

Published in: Open forum infectious diseases (2023)

Antifungal therapeutic drug monitoring (TDM) is recommended for hospitalized patients receiving itraconazole, posaconazole, or voriconazole for treatment or prophylaxis. In this analysis of hospital-based data, TDM was uncommonly performed (15.8%) in a large cohort of eligible patients, suggesting missed opportunities to avoid subtherapeutic drug levels and minimize toxicity.

Keyphrases

end stage renal disease
candida albicans
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
emergency department
electronic health record